Revenue of Paroxysmal Nocturnal Hemoglobinuria Drug Market Size to Reach $8.9 Billion by 2030, Forecasted to Grow at 12.5% CAGR

Denver, CO, July 14, 2023 (GLOBE NEWSWIRE) -- Zion Market Research has published a new research report titled “Paroxysmal Nocturnal Hemoglobinuria Drug Market By Treatment (Medication, Supplements, Blood Transfusion, And Bone Marrow Transplant), By Drugs (Eculizumab, Ravulizumab, And Others), By Route Of Administration (Oral And Parenteral), By Distribution Channel (Direct, Online Pharmacy, Retailers, And Others), By End User (Hospitals, Homecare, Specialty Clinics, And Others) And By Region - Global And Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, And Forecasts 2023 – 2030” in its research database.

“According to the latest research study, the demand of global Paroxysmal Nocturnal Hemoglobinuria Drug Market size & share in terms of revenue was valued at USD 3500 million in 2022 and it is expected to surpass around USD 8.9 billion mark by 2030, growing at a compound annual growth rate (CAGR) of approximately 12.5% during the forecast period 2023 to 2030.”

What is Paroxysmal Nocturnal Hemoglobinuria Drug? How big is the Paroxysmal Nocturnal Hemoglobinuria Drug Industry?

Paroxysmal Nocturnal Hemoglobinuria Drug Report Coverage & Overview:

The paroxysmal nocturnal hemoglobinuria (PNH) drug market refers to the pharmaceutical industry's segment that focuses on the development, production, and distribution of medications for the treatment of PNH. PNH is a rare and potentially life-threatening blood disorder characterized by the abnormal breakdown of red blood cells, leading to a range of symptoms such as anemia, blood clots, and organ damage. The introduction of targeted therapies has revolutionized the management of PNH, providing improved outcomes and quality of life for patients. Eculizumab (trade name Soliris) was the first targeted therapy approved for PNH and has been a cornerstone of treatment for many years. It works by inhibiting the complement system, which is responsible for the destruction of red blood cells in PNH. Ravulizumab (trade name Ultomiris) is a more recent addition to the PNH treatment landscape, offering an extended dosing interval compared to eculizumab.

The PNH drug market is driven by several factors, including the growing prevalence of PNH, increased awareness and diagnosis, advancements in drug research & development, and favorable regulatory environments. However, the market also faces challenges such as high treatment costs, limited patient population, regulatory & reimbursement barriers, and the need for alternative treatment options. Pharmaceutical companies, healthcare providers, patient advocacy groups, and regulatory bodies play crucial roles in shaping the PNH drug market. Ongoing research and development efforts aim to further enhance treatment options, develop alternative therapies, and improve patient outcomes. The paroxysmal nocturnal hemoglobinuria drug market's future outlook is influenced by factors such as emerging therapies, evolving healthcare policies, and advancements in diagnostic capabilities.

Get a Free Sample PDF of this Research Report for more Insights with a Table of Content, Research Methodology, and Graphs - https://www.zionmarketresearch.com/sample/paroxysmal-nocturnal-hemoglobinuria-drug-market

(A free sample of this report is available upon request; please contact us for more information.)

Our Free Sample Report Consists of the Following:

• Introduction, Overview, and in-depth industry analysis are all included in the 2023 updated report.
• The COVID-19 Pandemic Outbreak Impact Analysis is included in the package
• About 214+ Pages Research Report (Including Recent Research)
• Provide detailed chapter-by-chapter guidance on Request
• Updated Regional Analysis with Graphical Representation of Size, Share, and Trends for the Year 2023
• Includes Tables and figures have been updated
• The most recent version of the report includes the Top Market Players, their Business Strategies, Sales Volume, and Revenue Analysis
• Zion Market Research research methodology

(Please note that the sample of this report has been modified to include the COVID-19 impact study prior to delivery.)

Global Paroxysmal Nocturnal Hemoglobinuria Drug Market: Growth Dynamics

The U.S. Food and Drug Administration (FDA) has approved an increasing number of PNH treatments, including iron supplements, blood transfusions, blood thinners, eculizumab (Soliris), and bone marrow transplants. This is expected to cause a significant increase in the global market for paroxysmal nocturnal hemoglobinuria (PNH) therapeutics over the forecast period. Additionally, there are ongoing research and development projects to create paroxysmal nocturnal hemoglobinuria (PNH) medication that is affordable and is anticipated to propel the market for therapies for PNH toward growth. The market is growing as a result of the increasing frequency of blood diseases. During the projected period, the paroxysmal nocturnal hemoglobinuria drug market expansion is anticipated to be fueled by the introduction of biologics that aim to treat the underlying problem behind a hemolytic defect or an aberrant hematopoietic stem cell. The high unmet need for drugs in emerging nations is also fueling market expansion.

Further, the paroxysmal nocturnal hemoglobinuria drug industry is expanding as a result of increased government, public, and private organization investment in the discovery of innovative pharmaceuticals. The market's ability to expand is being constrained by the high cost of medication and surgical procedures such as stem cell transplantation (SCT). During the projection period, unfavorable side effects of existing therapies might restrain market expansion. An unfavorable reimbursement environment in emerging nations is impeding the market's expansion. The dangers of bone marrow transplantation are limiting market expansion.

The global paroxysmal nocturnal hemoglobinuria drug industry is segmented based on treatment, drugs, route of administration, distribution channel, end-user, and region.

Directly Purchase a copy of the report with TOC @ https://www.zionmarketresearch.com/buynow/su/paroxysmal-nocturnal-hemoglobinuria-drug-market

Report Scope

Paroxysmal Nocturnal Hemoglobinuria Drug Market: Segmentation Analysis

The global paroxysmal nocturnal hemoglobinuria drug industry is segmented based on treatment, drugs, route of administration, distribution channel, end-user, and region.

Based on the treatment, the global market is bifurcated into medication, supplements, blood transfusion, and bone marrow transplants. The medication segment is expected to grow at the fastest rate during the forecast period. The segment growth is attributed to the approval of various types of drugs.

Based on the drugs, the global paroxysmal nocturnal hemoglobinuria drug industry is divided into eculizumab, ravulizumab, and others.

Based on the route of administration, the global market is divided into oral and parenteral.

Based on the distribution channel, the global paroxysmal nocturnal hemoglobinuria drug industry is segmented into direct, online pharmacies, retailers, and others.

Based on the end user, the global paroxysmal nocturnal hemoglobinuria drug industry is segmented into hospitals, homecare, specialty clinics, and others.

The global Paroxysmal Nocturnal Hemoglobinuria Drug market is segmented as follows:

By Treatment

• Medication
• Supplements
• Blood Transfusion
• Bone Marrow Transplant

By Drugs

• Eculizumab
• Ravulizumab
• Others

By Route of Administration

• Oral
• Parenteral

By Distribution Channel

• Direct
• Online Pharmacy
• Retailers
• Others

By End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Browse the full “Paroxysmal Nocturnal Hemoglobinuria Drug Market By Treatment (Medication, Supplements, Blood Transfusion, And Bone Marrow Transplant), By Drugs (Eculizumab, Ravulizumab, And Others), By Route Of Administration (Oral And Parenteral), By Distribution Channel (Direct, Online Pharmacy, Retailers, And Others), By End User (Hospitals, Homecare, Specialty Clinics, And Others) And By Region - Global And Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, And Forecasts 2023 – 2030” Report at https://www.zionmarketresearch.com/report/paroxysmal-nocturnal-hemoglobinuria-drug-market

Competitive Landscape

Some of the main competitors dominating the global Paroxysmal Nocturnal Hemoglobinuria Drug market include - 

• Apellis Pharmaceuticals
• Alexion Pharmaceuticals Inc
• Akari Therapeutics Plc
• CinnaGen Co
• Ra Pharmaceuticals Inc
• Amgen Inc
• Achillion Pharmaceuticals Inc
• Alnylam Pharmaceuticals Inc
• F. Hoffmann-La Roche Ltd
• Novartis AG
• Regeneron Pharmaceuticals Inc
• BIOCAD
• Samsung Bioepis
• Amyndas Pharmaceuticals
• Teva Pharmaceutical Industries Ltd.
• LGM Pharma.
• Lannett
• NorthStar Rx LLC
• Abbott
• Cook
• Par Pharmaceutical

Key Insights from Primary Research:

• As per the analysis shared by our research analyst, the global paroxysmal nocturnal hemoglobinuria drug market is estimated to grow annually at a CAGR of around 12.5% over the forecast period (2023-2030).
• In terms of revenue, the global paroxysmal nocturnal hemoglobinuria drug market size was valued at around USD 3500 million in 2022 and is projected to reach USD 8900 million, by 2030.
• The increasing regulatory approvals for PNH drugs are expected to drive the growth of the paroxysmal nocturnal hemoglobinuria drug market during the forecast period.
• Based on the treatment, the blood transfusion segment is expected to capture the largest market share over the forecast period.
• Based on the end user, the hospital segment is expected to dominate the market during the forecast period.
• Based on region, North America is expected to hold the largest market share during the forecast period.

Have Any Query? Ask Our Experts: https://www.zionmarketresearch.com/inquiry/paroxysmal-nocturnal-hemoglobinuria-drug-market

Key questions answered in this report:

• What is the market size and growth rate forecast for Paroxysmal Nocturnal Hemoglobinuria Drug industry?
• What are the main driving factors propelling the Paroxysmal Nocturnal Hemoglobinuria Drug Market forward?
• What are the leading companies in the Paroxysmal Nocturnal Hemoglobinuria Drug Industry?
• What segments does the Paroxysmal Nocturnal Hemoglobinuria Drug Market cover?
• How can I receive a free copy of the Paroxysmal Nocturnal Hemoglobinuria Drug Market sample report and company profiles?

Key Offerings:

• Market Size & Forecast by Revenue | 2023−2030
• Market Dynamics – Leading Trends, Growth Drivers, Restraints, and Investment Opportunities
• Market Segmentation – A detailed analysis By Treatment, By Drugs, By Route of Administration, By Distribution Channel, By End User, and By Region
• Competitive Landscape – Top Key Vendors and Other Prominent Vendors

Request for Customization on this Report as per your requirements - https://www.zionmarketresearch.com/custom/7340

(We tailor your report to meet your specific research requirements. Inquire with our sales team about customising your report.)

Regional Analysis:

North America is expected to dominate the global paroxysmal nocturnal hemoglobinuria drug market over the forecast period. Reimbursement policies and coverage by public and private insurance systems impact the accessibility of PNH drugs in North America. The availability of reimbursement for targeted therapies varies across different U.S. states and Canadian provinces, with insurance coverage plays a crucial role in patient access and affordability. Thereby, driving the growth of the market over the forecast period.

By Region

• North America
  • U.S.
  • Canada
  • Rest of North America
• Europe
  • France
  • UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America

Recent Developments

• In April 2023, Novartis released comprehensive findings from the Phase III APPOINT-PNH study of experimental oral monotherapy iptacopan in people with paroxysmal nocturnal hemoglobinuria (PNH) who had not previously used complement inhibitors (including anti-C5 treatments). The trial exhibited clinically significant advantages across secondary goals and fulfilled its primary endpoint1. These findings were presented at the European Society for Blood and Marrow Transplantation's (EBMT) 49th Annual Meeting.

To know an additional revised 2023 list of market players, request a brochure of the report: https://www.zionmarketresearch.com/requestbrochure/paroxysmal-nocturnal-hemoglobinuria-drug-market

Browse Other Related Research Reports from Zion Market Research:

Aspergillus Drugs Market: Global Industry Perspective, Comprehensive Analysis and Forecast, 2018-2025: https://www.zionmarketresearch.com/report/aspergillus-drugs-market

High Purity Tin Market: Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018-2025: https://www.zionmarketresearch.com/report/high-purity-tin-market

Pneumatic Tube System Market: Global Industry Perspective, Comprehensive Analysis and Forecast, 2018-2025: https://www.zionmarketresearch.com/report/pneumatic-tube-system-market

Limonin Market: Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018-2025: https://www.zionmarketresearch.com/report/limonin-market

Cigarette Lighter Market: Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018-2025: https://www.zionmarketresearch.com/report/cigarette-lighter-market

Photopheresis Products Market: Global Industry Perspective, Comprehensive Analysis and Forecast, 2018-2025: https://www.zionmarketresearch.com/report/photopheresis-products-market

Asia Pacific Organic Peroxide Market: Asia Pacific Industry Perspective, Comprehensive Analysis, and Forecast, 2018-2025: https://www.zionmarketresearch.com/report/asia-pacific-organic-peroxide-industry

Gym Management Software Market: Global Industry Perspective, Comprehensive Analysis and Forecast, 2018-2025: https://www.zionmarketresearch.com/report/gym-management-software-market

Property Management Software Market: Global Industry Perspective, Comprehensive Analysis and Forecast, 2018-2025: https://www.zionmarketresearch.com/report/property-management-software-market

Industrial Robot Market: Global Industry Perspective, Comprehensive Analysis and Forecast, 2018-2025: https://www.zionmarketresearch.com/report/industrial-robot-market

Poultry Vaccine Market: Global Industry Perspective, Comprehensive Analysis and Forecast, 2018-2025: https://www.zionmarketresearch.com/report/poultry-vaccine-market

Simultaneous localization and mapping (SLAM) Robot Market: Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018-2025: https://www.zionmarketresearch.com/report/simultaneous-localization-and-mapping-robot-market

Active Insulation Market: Global Industry Perspective, Comprehensive Analysis and Forecast, 2018-2025: https://www.zionmarketresearch.com/report/active-insulation-market

Cast Polypropylene (CPP) Films Market: Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018-2025: https://www.zionmarketresearch.com/report/cast-polypropylene-films-industry

3D Animation Software Market: Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018-2025: https://www.zionmarketresearch.com/report/3d-animation-software-market

About Zion Market Research:

Zion Market Research is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Zion Market Research are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds.

Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.

Follow Us on LinkedIn: https://www.linkedin.com/company/zion-market-research/

Follow Us on Twitter: https://twitter.com/zion_research

Follow Us on Facebook: https://www.facebook.com/zionmarketresearch

Follow Us on Pinterest: https://www.pinterest.com/zionmarketresearch/

Follow Us on YouTube: https://youtu.be/Y0Yfi7N8zSs

Contact Us:

Rushikesh Dorge

USA: +1 347 690-0211

United Kingdom: +44 2032 894158

Japan: +81 50 5806 9039

India: +91 7768 006 007

Web: https://www.zionmarketresearch.com/

Blog: https://zmrblog.com/

Still, Looking for More Information? OR Want Data for Inclusion in Magazine, Case Study, or Media?

Email Directly Here with Detail Information: sales@zionmarketresearch.com